Innovative Phase 1 Study of RD140 Showcases Promising Results in Treating Relapsed Multiple Myeloma

Promising Outcomes in RD140 Clinical Study

On September 25, 2026, IASO Bio, a pioneering biopharmaceutical company, presented the exciting initial data from the first-in-human Phase 1 clinical trial of RD140. This cutting-edge therapy targets both BCMA and GPRC5D, aiming for advanced treatment of relapsed or refractory multiple myeloma (R/R MM) and plasma cell leukemia (PCL). Conducted at the prestigious International Myeloma Society (IMS) Annual Meeting, it outlined outcomes that have the potential to transform treatment strategies for patients with these challenging conditions.

Study Overview

The trial design involved recruiting nine heavily pretreated patients, all at high-risk for disease progression. These subjects had undergone at least three previous treatments, qualifying them for RD140 infusion after undergoing lymphodepletion conditioning with cyclophosphamide and fludarabine. Early results of this innovative therapy were impressive: an overall objective response rate (ORR) of 88.9% was observed, with the higher-dose cohort achieving a perfect 100% ORR. Additionally, a significant 88.9% of participants experienced minimal residual disease (MRD) negativity, indicating a deep therapeutic response.

Professor Jin Lu from Peking University People's Hospital, who led the research effort, expressed enthusiasm about the findings, stating, "The ORR of 88.9% and the high MRD negativity rate achieved in this heavily pretreated group underscore the efficacy of RD140 as a promising future treatment for patients battling relapsed multiple myeloma and plasma cell leukemia."

Safety and Tolerability

One of the most notable aspects of RD140’s profile is its safety. The study reported no cases of neurotoxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS). Instead, while some patients experienced cytokine release syndrome (CRS), these instances were predominantly low grade, with minimal side effects observed overall. The safety results confirm the product's potential as a viable treatment option, especially given the pressing needs in this patient demographic.

Efficient Manufacturing Process

An additional benefit of RD140 lies in its rapid manufacturing capabilities. Thanks to the FasT CAR-T platform, the manufacturing of this therapy can be completed within just 3 to 4 days. This speed is crucial, especially for critically ill patients requiring expedited treatment.

Future Directions

The initial findings pave the way for further investigations into RD140’s efficacy and safety among larger patient cohorts and extended follow-up periods. The encouraging early results affirm the necessity for ongoing research into dual-targeted CAR-T therapies, particularly as they could redefine standards of care in hematologic malignancies.

In conclusion, the Phase 1 study of RD140 highlights a significant advancement in the quest for effective treatments for relapsed/refractory multiple myeloma and plasma cell leukemia. As IASO Bio continues to explore this promising avenue, the potential impact on patient survival and quality of life could be profound. With a solid foundation laid by these preliminary results, the future looks bright for RD140 and the patients it aims to serve.